Patient Information Sheet - Hydroquinone with EGCg (in W06™*)

This medicine was compounded specifically for you in a pharmacy in order to fill the prescription your doctor wrote for you. It was specifically made to meet your individual needs. For this reason, no standardized information or literature is available with your prescription. If you have not done so, please discuss this medicine with your doctor to ensure that you understand (1) why a compounded medication has been prescribed, (2) how to properly take this medication, and (3) the interactions, if any, this medicine may have with any other medicines you are taking.

Compounding is a long-standing pharmacy practice that allows doctors to treat their patients' individual needs without being restricted only to off-the-shelf medicines or devices. This medicine was prepared in a compounding pharmacy to meet the specifications ordered by your doctor.

Call your doctor if you experience any side effects, if you are taking additional medicines that may interact with this compounded medicine, or if you have allergies or other medical conditions that should be noted. Call our pharmacists if information on the label is not clear to you or you have any concerns regarding precautions, ingredients, or proper storage. Our pharmacists are available to address any additional questions or concerns.

Medication: This medication contains hydroquinone, a skin-lightening agent, and EGCg, a component of green tea, in W06™ base. The base offers a smooth and creamy application and has moisturizing and softening properties.

Use: Hydroquinone is generally prescribed to treat hyperpigmentation of the skin. EGCg may be prescribed for a range of uses, including reduction in inflammation, rosacea, acne, prevention of keloids, or for antifungal or antiviral properties.

Side Effects: Topical use often provides more localized effects of medication. Side effects are reduced when bypassing vital organs. For the first two to three weeks of treatment, your skin condition may appear to worsen. Stinging, peeling or a feeling of facial warmth are possible. Dry skin and redness are common side effects.

Precautions: Limit exposure to sunlight and use sunscreen during treatment.

Dosage and Administration: This medication is typically dispensed in a pump for topical application. Completely wash and dry application area prior to use. Apply a thin layer to affected areas once daily, preferably at bedtime. Gently rub in the medication until it is evenly distributed. For best use, do not use other moisturizers or cleansers on the medicated area for at least one hour.

Storage, Beyond Use Dating and Disposal: This medication should be stored at controlled room temperature (68-77℉) and protected from light. The Beyond Use Date is a scientifically derived "expiration" date for each unique formulation, and storage depends on the stability of each individual formulation. Please refer to your medication label and auxiliary labels for specific storage requirements and beyond use dating. For information on medication destruction, please visit www.fda.gov and search how to dispose of unused medicines.

NORTH LAMAR	SOUTH LAMAR	WESTLAKE	LAKELINE	COMPOUNDING CENTER
4018 N. Lamar Blvd.	3801B S. Lamar Blvd.	2805 Bee Caves Rd., Ste. 416	13860 Research Blvd., Unit C	4120 Commercial Center Dr. #400
Austin, TX 78756	Austin, TX 78704	Austin, TX 78746	Austin, TX 78717	Austin, TX 78744
512.459.9090	512.444.8866	512.327.8877	512.219.9499	512.646.4007

www.PeoplesRx.com

*W06™ is a proprietary base designed by Pharmacy Compounding Centers of America (PCCA®)

Disclaimer: This Patient Information Sheet explains the proper use and storage of the described medication and is provided as a service to our customers. This guideline is a summary of information and is not intended to replace or act as an official drug monograph. Patients with further questions or concerns specific to this compounded medication should consult their pharmacist. Patients with questions regarding therapy not discussed above should consult their doctor.

Last update: February 2019